Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$17,500.00

Role of H-Ras Prenylation in Synaptic Failure of Alzheimer’s Disease

EF 2013-14

Résumé
Alzheimer's disease (AD) is a prominent age-related health problem that will get worse as people live longer. Calamitous memory loss and dementia are major symptoms surfacing in people with AD, and force them into continual care. Thus, AD takes a toll not only on the person suffering the disease, but also on family members of patients, emotionally and economically, through costs of care and/or lost income from not having time to work. The urgency for effective treatment has never been greater, but we must understand AD better to develop new ways of treating it. A hallmark of AD is plaque development in specific areas of brain tissue. These plaques are concentrated with a substance called beta-amyloid peptide (Aí). This substance has many negative effects for brain cells that eventually leads to them dying off. Before the cells die, they lose the ability to communicate with other cells, which results in memory failure for the person suffering with the disease. In this project I will focus on the effect of Aí on the synapses, which are the point of communication between brain cells and allow flow of information. Formation of synapses is crucial for learning and memory, and it is known that Aí decreases the number of these points of communication. Synapses are strengthened when they are used more, which demands protein to build up their structure. Synapses form between spines of neighboring brain cells to shorten the communication gap. This process results from dynamic interactions between cellular proteins that require trafficking mechanisms to reach their proper destinations within cells. One trafficking mechanism is protein prenylation: the process of attaching a fat molecule to a protein molecule. This allows the protein to help strengthen the synapse. Our lab has demonstrated that Aí can inhibit protein prenylation, which may impair synapse strengthening and lead to unstable brain cell communication. Brain cells lack function when they are not communicating, and tend to die off. Our lab is focused on specific proteins that Aí interacts with to impair synapses. Our aim is to study how synapse density is altered in brain slices from mice models of AD. We expect these mice to exhibit a significant decrease in their number of synapses. To determine if this decrease is due to inhibited prenylation, we will apply appropriate fat molecules to rescue prenylation, which should prevent synapse loss. Preventing synapse loss translates into preventing memory loss, which is the devastating symptom of AD.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
311669
Name
Smith Kevan T
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Role of H-Ras Prenylation in Synaptic Failure of Alzheimer’s Disease
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S; Beta-Amyloid; Hippocampus; Neurodegeneration; Neuroscience; Organotypic; Pharmacology; Plasticity; Prenylation; Synapse
Abstract
Alzheimer's disease (AD) is a prominent age-related health problem that will get worse as people live longer. Calamitous memory loss and dementia are major symptoms surfacing in people with AD, and force them into continual care. Thus, AD takes a toll not only on the person suffering the disease, but also on family members of patients, emotionally and economically, through costs of care and/or lost income from not having time to work. The urgency for effective treatment has never been greater, but we must understand AD better to develop new ways of treating it. A hallmark of AD is plaque development in specific areas of brain tissue. These plaques are concentrated with a substance called beta-amyloid peptide (Aí). This substance has many negative effects for brain cells that eventually leads to them dying off. Before the cells die, they lose the ability to communicate with other cells, which results in memory failure for the person suffering with the disease. In this project I will focus on the effect of Aí on the synapses, which are the point of communication between brain cells and allow flow of information. Formation of synapses is crucial for learning and memory, and it is known that Aí decreases the number of these points of communication. Synapses are strengthened when they are used more, which demands protein to build up their structure. Synapses form between spines of neighboring brain cells to shorten the communication gap. This process results from dynamic interactions between cellular proteins that require trafficking mechanisms to reach their proper destinations within cells. One trafficking mechanism is protein prenylation: the process of attaching a fat molecule to a protein molecule. This allows the protein to help strengthen the synapse. Our lab has demonstrated that Aí can inhibit protein prenylation, which may impair synapse strengthening and lead to unstable brain cell communication. Brain cells lack function when they are not communicating, and tend to die off. Our lab is focused on specific proteins that Aí interacts with to impair synapses. Our aim is to study how synapse density is altered in brain slices from mice models of AD. We expect these mice to exhibit a significant decrease in their number of synapses. To determine if this decrease is due to inhibited prenylation, we will apply appropriate fat molecules to rescue prenylation, which should prevent synapse loss. Preventing synapse loss translates into preventing memory loss, which is the devastating symptom of AD.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Smith, Kevan T
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~